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Abstract
Sterile inflammation is considered critical in the pathogenesis of diabetic
nephropathy (DN). Here we show that Fetuin-A (FetA) or lipopolysaccharide
(LPS) exacerbate palmitic acid-induced podocyte death, which is associated
with a strong induction of monocyte chemoattractant protein-1 (MCP-1) and
keratinocyte chemoattractant (KC). Moreover, blockage of TLR4 prevents
MCP-1 and KC secretion and attenuates podocyte death induced by palmitic
acid alone or combined with FetA. In addition, inhibition of interleukin-1
(IL-1) signaling by anakinra, a recombinant human IL-1Ra, or a murinized
anti-IL-1b antibody attenuates the inflammatory and ultimate cell death
response elicited by FetA alone or combined with palmitic acid. In vivo short-
term therapy of diabetic DBA/2J mice with an anti-IL1-b antibody for
4 weeks prevented an increase in serum FetA and considerably decreased uri-
nary tumor necrosis alpha (TNF-a), a known risk factor for DN progression.
In summary, our results suggest that FetA similarly to LPS leads to an inflam-
matory response in podocytes, which exacerbates palmitic acid-induced podo-
cyte death and our data imply a critical role for IL-1b signaling in this
process. The study offers the rational for prolonged in vivo studies aimed at
testing anti-IL-1b therapy for prevention and treatment of DN.
Introduction
Diabetic nephropathy (DN) has become a leading cause
of end-stage renal disease in industrialized countries, and
most affected patients have type 2 diabetes (USRDS,
2003; Locatelli et al. 2004). Over the last few years it has
become evident that sterile inflammation plays a central
role in the pathogenesis of DN (Lim and Tesch 2012).
Accumulation of macrophages was demonstrated in
humans and rodent models of DN (Chow et al. 2004;
Nguyen et al. 2006), and inhibition of inflammatory cell
recruitment into the kidney protects from experimental
DN (Chow et al. 2005; Awad et al. 2011). In addition to
immune cells, intrinsic renal cells, such as podocytes and
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mesangial cells, can secrete proinflammatory cytokines,
which may contribute to the inflammatory process and
aggravate DN (Tesch et al. 1997; Sayyed et al. 2009).
Interleukin-1b (IL-1b) is a master regulator of inflam-
mation in various tissues (Dinarello 2009). Intrinsic renal
cells including podocytes are sources of IL-1b in experi-
mental models of glomerulonephritis (Niemir et al.
1997). The potential role of IL-1b in the pathogenesis of
DN dates back to 1996 when it was reported that a low
expressing allele of the IL-1 receptor antagonist (IL-1Ra),
which implies increased IL-1 signaling, is associated with
DN (Blakemore et al. 1996). More recently, it was
reported that IL-1b is elevated in plasma and in renal
cortex extracts at the onset of DN, and anakinra, a
recombinant human IL-1Ra, can prevent or even reverse
DN in different mouse models (Shahzad et al. 2015).
Toll-like receptors (TLRs) are considered to play a key
role in the inflammatory response underlying diabetes
and its complications (Lin and Tang 2014). TLRs recog-
nize pathogen-associated molecular patterns such as
lipopolysaccharide (LPS), and viral or bacterial nucleic
acids (Akira et al. 2001). Activation of TLRs leads to a
recruitment of adaptor proteins, which subsequently trig-
ger downstream signaling cascades resulting in activation
of nuclear factor-jB (NF-jB) (Akira et al. 2001). The
transcription factor NF-jB induces a wide range of
cytokines including IL-1b (Hiscott et al. 1993), and
monocyte chemoattractant protein-1 (MCP-1) (Ueda
et al. 1994). TLRs are not only activated by pathogen-
associated molecular patterns, but also by endogenous
danger signals released during tissue injury or metabolic
stress (Akira et al. 2001).
Type 2 diabetes mellitus is characterized by hyper-
glycemia and dyslipidemia with increased levels of free
fatty acids (FFAs) (Randle et al. 1963). Over the past
years, evidence has accumulated that FFAs can induce the
production of proinflammatory cytokines through activa-
tion of TLR4 and/or TLR2 (Lee et al. 2001; Shi et al.
2006; Boni-Schnetzler et al. 2009). However, the mecha-
nism how FFAs activate TLRs is under debate and current
evidence suggests that FFAs do not directly bind to TLR4
(Erridge and Samani 2009). Recently, it was suggested
that Fetuin-A (FetA) may act as an endogenous ligand
and molecular linker for FFAs to TLR4 (Pal et al. 2012).
FetA is a liver-derived, abundant plasma protein with
multiple biological functions. FetA is known as a major
carrier protein of FFAs in the circulation (Cayatte et al.
1990). As fetal bovine serum (FBS) contains about
20 mg/mL FetA, cell culture media with 10% FBS contain
a considerable amount of FetA and therefore may explain
previous reports suggesting that FFAs directly activate
TLR4 (Pal et al. 2012). Importantly, studies targeting
TLR4 genetically or pharmacologically revealed
renoprotective effects in various murine models of DN
(Kuwabara et al. 2012; Cha et al. 2013).
In the pathogenesis of DN, podocyte injury and loss
are critical events (Wolf et al. 2005) and they precede
albuminuria (Pagtalunan et al. 1997; Meyer et al. 1999;
Dalla Vestra et al. 2003). Previously, we reported that
podocytes are highly susceptible to the saturated FFA pal-
mitic acid leading to podocyte death (Sieber et al. 2010).
Mechanistically, palmitic acid-induced podocyte death is
linked to endoplasmic reticulum stress (Sieber et al.
2010), and its toxicity can be attenuated by monounsatu-
rated FFAs by upregulation of stearoyl-CoA desaturase 1
(Sieber et al. 2013), an enzyme converting saturated to
monounsaturated FFAs, or by stimulation of fatty acid
oxidation (Kampe et al. 2014). Whether inflammation
contributes to palmitic acid-induced podocyte death is
currently unknown.
The objective of the present study was to investigate
whether palmitic acid, FetA, or their combination elicits
an inflammatory response in podocytes and whether they
modify podocyte survival. In addition, we explored the
potential role of TLR4 and IL-1 signaling in these pro-
cesses. In complementary in vivo studies, the short-term
effect of a murinized anti-IL-1 antibody was tested on
serum FetA as well as on surrogate markers of DN.
Materials and Methods
Animal and experimental protocol
All experimental procedures were performed in accor-
dance with and approved by the Swiss veterinary law and
institutional guidelines. Eight-week-old DBA/2J (DBA)
male mice were purchased from Charles River (Sulzfeld,
Germany). Mice were maintained in 12-h light/12-h dark
cycle, and provided food and water ad libitum. Mice were
allowed to acclimatize to the animal facility for 1 week
prior to experiment initiation.
Induction of diabetes and anti-IL-1b
treatment
Diabetes was induced in 8-week-old DBA mice by daily
intraperitoneal (i.p.) injections of 40 mg/kg of streptozo-
tocin (STZ; Sigma-Aldrich, St. Louis, MO) for five con-
secutive days, freshly prepared in 50 mmol/L sodium
citrate buffer at pH 4.5. Control mice were injected with
sodium citrate buffer alone. One week after the last STZ
injection, hyperglycemic mice (glucose ≥ 14 mmol/L)
were fed a high-fat diet (HFD) for 4 weeks. HFD was
purchased from ssniff GmbH, Germany, containing 60%
of fat (lard) (catalog no. E15742-34). Anti-IL-1b antibody
was kindly provided by Novartis (Basel, Switzerland),
2017 | Vol. 5 | Iss. 10 | e13287
Page 2
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
Fetuin-A Exacerbates Podocyte Death J. M. Orellana et al.
under a signed material transfer agreement (2015). Anti-
IL-1b antibody was injected i.p. weekly at 10 mg/kg of
body weight for the first 2 weeks and at 5 mg/kg for the
following 2 weeks. Vehicle (saline solution) was injected
to the control group.
Measurement of blood glucose, serum FetA,
and urinary TNF-a and albumin levels
Fasting blood glucose was determined with a Glucometer
(Freestyle; Abbott Diabetes Care, Inc., Alameda, CA) from
tail vein blood of 6 h fasted mice. Serum FetA and uri-
nary tumor necrosis alpha (TNF-a) were measured using
Duoset ELISA kit (R&D Systems) and mesoscale assays
(Mesoscale Discovery, Rockville, MD) according to the
manufacturer’s instructions. Urinary albumin levels were
determined using the albuminuria kit from Exocell
(Philadelphia).
Materials
Palmitic acid (P9767), low endotoxin and fatty acid free-
bovine serum albumin (BSA) (A8806), LPS (L2630), and
IL-1b (I5271) were purchased from Sigma (St. Louis,
MO). Recombinant murine interferon-gamma (CTK-358-
2PS) was from MoBiTec (Goettingen, Germany). Type-1
collagen was from BD Biosciences. Annexin V (A23204)
and propidium iodide (P3566) were from Invitrogen
(Eugene, Oregon).
Anakinra (Kineret) was purchased from SOBI (Swed-
ish Orphan Biovitrum AB). TAK-242 (tlrl-cli95) was from
InvivoGen (Distributed by LabForce AG, Switzerland).
Murinized Anti-IL-1b Ab is a noncommercialized product
provided by Novartis. Bovine FetA was kindly provided
by Prof. Jahnen-Dechent, Aachen University, Germany,
and the levels of endotoxins were tested in his laboratory
with Endosafe ultrasensitive PTS, Charles River. Murine
FetA was donated by Prof. Bhattacharya, Visva-Bharati
University, West Bengal, India. Experiments shown in
Figure 1C and D were performed with murine FetA. All
other experiments were done with bovine FetA.
Cell culture, FFA preparation, and apoptosis
assay
Murine podocytes were cultured as described previously
(Sieber et al. 2010). Podocytes were differentiated for at
least 11 days before starting experiments. All experiments
were carried out in six-well plates except for isolating
protein or RNA for which 10 cm dishes were used. FFA
preparations were done as described previously. The final
concentration of palmitic acid was 200 lmol/L complexed
to BSA (0.2%), if not otherwise stated. Annexin V and PI
stainings were performed as reported earlier (Sieber et al.
2010). Flow cytometry was carried out with CyAnTM ADP
Analyzer (Beckman Coulter) and 20,000 cells were
counted. Data from flow cytometry were analyzed using
FLOWJO (Tree Star, Inc., Ashland, OR) software.
Annexin V-positive/PI-negative podocytes were consid-
ered apoptotic, whereas Annexin V-positive/PI-positive
podocytes were considered (late apoptotic) necrotic cells.
Removal and measurement of endotoxins
FFA preparations, BSA, and bovine and murine FetA were
depleted from potential endotoxin contaminations with
EndoTrap HD (800063, Hyglos GmbH). Samples were
passed four times through Endotrap columns. Endotoxin
concentrations were subsequently measured with
ToxinSensor Chromogenic LAL Endotoxin Assay Kit
(L00350C, GenScript) according to the manufacturer’s
instructions if not otherwise indicated. All reactions were
strictly performed at a constant temperature of 37°C in a
heating block. Tips and plastic ware were endotoxin free.
During experimental conditions cells were exposed to
endotoxin concentrations of ≤ 0.15 EU/mL (≤ 0.015 ng/
mL).
TLR4 activation assay
TLR4 activation assay was done by using HEK-Blue hTLR4
reporter cells containing TLR4/NF-jB/SEAP purchased
from InvivoGen, CA, USA. Cells were cultured in 75 cm2
flask with DMEM (#41965, Invitrogen) media including
4.5 g/L glucose, 4 mmol/L L-glutamine, 10% FBS, peni-
cillin/streptomycin, and Normocin according to manufac-
turer’s instructions. For experiments involving TLR4
activation, HEK-BlueTM detection media without FBS was
used. Experiments were done in 96-well plates with
150 lmol/L palmitic acid in the presence of FetA ranging
from 0 to 150 lg/mL or LPS from 10 to 104 pg/mL for
6 h. Secreted SEAP downstream of TLR4 activation
induced a color reaction of the cell culture media (purple
to blue) and the absorbance was quantified with a Synergy
H1 hybrid reader (BioTek) at 640 nm.
Measurement of cytokine and chemokine
expression
Differentiated podocytes were cultured in 75 cm2 flasks
and were re-seeded in 96-well plates for 24 h, at
6000 cells/well. All experiments were performed under
serum starvation conditions (RPMI-1640, with 0.2% heat-
inactivated FBS and 5 mmol/L glucose) including a 16-h
preincubation to synchronize the cells. MCP1 and KC
expression was quantified using Duoset ELISA kit
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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according to manufacturer’s protocol (DY479 for MCP-1;
DY453 for KC, R&D Systems purchased from Zug,
Switzerland).
Statistical analysis
All experiments were performed at least 4 times if not
otherwise indicated. Data are expressed as means  SD.
Analysis of variance (ANOVA) and Bonferroni t-tests
were used for statistical analysis using GraphPad Prism 6
software.
Results
FetA but not palmitic acid or oleic acid
stimulate MCP-1 or KC secretion in
podocytes
To investigate whether palmitic acid leads to an inflam-
matory response in podocytes, we measured MCP-1 and
KC in the cell culture media of podocytes after incubation
with 75 lmol/L palmitic acid (complexed to BSA) for
12 h. As shown in Figure 1A and B, palmitic acid did not
stimulate the secretion of these cytokines compared to the
control media with BSA alone. As it has been suggested
that FetA may be necessary to elicit an inflammatory
response by palmitic acid (Pal et al. 2012), podocytes
were incubated with FetA or FetA in combination with
palmitic acid (Fig. 1A and B). In contrast to palmitic
acid, FetA significantly stimulated MCP-1 and KC secre-
tion by 368  57% (P < 0.001) and 1729  135%
(P < 0.001), respectively. The combination of FetA and
palmitic acid led to a further increase in MCP-1 and KC
by 129  28% (P < 0.001) and 94  3% (P < 0.001),
respectively, compared to FetA alone. As shown in Fig-
ure 1C, similar results were obtained with oleic acid,
which itself was not able to stimulate MCP-1 secretion
significantly. However, FetA in combination with oleic
acid increased MCP-1 by 73  10% (P < 0.0001) com-
pared to FetA.
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Figure 1. FetA but not palmitic acid or oleic acid stimulates MCP-1 or KC secretion in podocyte. (A) Graph shows MCP-1 expression after treating
podocytes with 75 lmol/L palmitic acid (palm) or bovine serum albumin (BSA) (control) either with or without 150–350 lg/mL bovine FetA. Bar
graph represents mean  SD MCP-1 levels (in pg/mL) in the supernatant after 12 h (n = 6, ***P < 0.001). (B) Graph shows KC expression after
treating podocytes with 75 lmol/L palm or BSA (control) either with or without 150–350 lg/mL bovine FetA. Bar graph represents mean  SD
KC levels (in pg/mL) in the supernatant after 12 h (n = 6, ***P < 0.001). (C) Graph shows MCP-1 expression in podocytes treated with 75 lg/mL
palm or 75 lg/mL oleic acid (oleic) alone or in combination with 200 lg/mL murine FetA. Bar graph represents mean  SD MCP-1 levels (in pg/
mL) in the supernatant after 16 h of treatment and 1 h of preincubation with TAK-242 (n = 4, ***P < 0.001). Insert: LPS induces MCP-1 release,
and TAK-242 prevents chemokine expression. Podocytes were treated with 5 ng/mL LPS. Bar graph represents mean  SD MCP-1 levels (in pg/
mL) in the supernatant after 16 h of treatment and 1 h of preincubation with TAK-242 (n = 4, **P < 0.01). (D) Graph shows TLR4 activation in
HEK-BlueTM hTLR4 cells treated with LPS (10 pg, 100 pg/mL, 103 pg/mL, 104 pg/mL) or 150 lmol/L palmitic acid in the presence of murine FetA
(0 lg/mL, 50 lg/mL, 100 lg/mL, 150 lg/mL) for 18 h. Bar graph represents mean percentages  SD of OD reading (n = 3).
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As the proinflammatory response of FetA is reported to
involve TLR4 (Pal et al. 2012), we inhibited TLR4 signal-
ing with TAK-242 (resatorvid), a specific small-molecule
inhibitor of TLR4 signaling (Matsunaga et al. 2011).
TAK-242 completely prevented the induced MCP-1 secre-
tion by the prototypic TLR4 ligand LPS (Fig. 1C, insert)
as well as by FetA in combination with palmitic or oleic
acid (Fig. 1C).
To further investigate the potential role of FetA in
stimulating TLR-4 signaling, we took advantage of a com-
mercially available TLR4 reporter HEK cell line. As shown
in Figure 1D, increasing concentrations of FetA from 50
to 150 lg/mL in the presence of a constant concentration
of 150 lmol/L palmitic acid dose dependently stimulated
TLR4 similar to the activation by LPS in the range from
10 pg to 10 ng/mL.
FetA moderately aggravates and inhibition
of TLR4 signaling attenuates palmitic
acid-induced podocyte death
To investigate whether FetA modulates cell death induced
by palmitic acid, podocytes were treated with FetA alone
or in combination with 200 lmol/L palmitic acid for
48 h. As shown in Figure 2A, FetA had no effect on
podocyte viability, but moderately exacerbated palmitic
acid-induced podocyte death. Specifically, FetA further
increased apoptosis in podocytes by 21  0% (P < 0.05).
An effect on necrotic podocytes was not consistently
observed, most likely due to higher variations and the
previously reported observation that necrotic podocytes
disintegrate, which ultimately leads to underestimation of
necrotic cells (Sieber et al. 2013). Similarly, LPS had no
visible effect on podocyte necrosis, but increased palmitic
acid-induced apoptosis by 29  7% (P < 0.001)
(Fig. 2B). TAK-242 prevented the FetA-induced increase
in apoptotic podocytes (Fig. 2A) as well as the increase
induced by LPS (Fig. 2B). Surprisingly, compared to
podocytes treated with palmitic acid alone, the presence
of TAK-242 decreased palmitic acid-induced apoptosis by
79  1% (P < 0.001) and necrosis by 65  5%
(P < 0.001) (Fig. 2A). This unexpected finding may indi-
cate modulation of podocyte death by a constitutive acti-
vation of TLR4 or additional protective off-target effects.
Anakinra and an anti-IL-1b antibody
attenuate MCP-1 expression induced by
FetA and palmitic acid
To investigate the potential involvement of IL-1b on FetA
and palmitic acid-induced MCP-1 secretion, podocytes
were cotreated in the presence or absence of the recombi-
nant human IL-1Ra antagonist anakinra and a murinized
neutralizing anti-IL-1b antibody for 16 h. As shown in
Figure 3, the anti-IL-1b antibody and anakinra reduced
MCP-1 secretion by 53  17% (P < 0.001) and by
30  9% (P < 0.001), respectively.
Anakinra and anti-IL-1b antibody attenuate
podocyte death induced by palmitic acid
and FetA
To examine whether IL-1 signaling plays a role in the
aggravating effect of FetA on palmitic acid-induced cell
death, podocytes were preincubated for 1 h with anti-IL-
1b or anakinra prior to the addition of palmitic acid or
the combination of palmitic acid and FetA for 48 h. Both
the anti-IL-1b antibody and anakinra significantly
reduced apoptosis by 34  6% (P < 0.05) and 30  6%
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(P < 0.05), and necrosis by 29  5% (P < 0.05) and
33  3% (P < 0.01), respectively (Fig. 4A).
Anakinra also partially prevented the exacerbating effect
of LPS on palmitic acid-induced apoptosis and necrosis
by 45  14% (P < 0.01) and 23  13%, respectively
(Fig. 4B). Interestingly, the anti-IL-1b antibody and ana-
kinra also attenuated podocyte death induced by palmitic
acid alone (Fig. 4B and C). Finally, we investigated
whether IL-1b induces podocyte death. IL-1b alone in a
dose range from 5 to 20 ng/mL did not affect the viability
of podocytes (data not shown); however, 5 ng/mL IL-1b
significantly exacerbated palmitic acid-induced podocyte
apoptosis and necrosis by 117  35% (P < 0.001) and
90  24% (P < 0.001), respectively (Fig. 4D).
Anti-IL-1b treatment reduces serum FetA
and urinary TNF-a levels in diabetic mice
To complement our in vitro findings, we performed a
pilot study to investigate the effect of the anti-IL-1b anti-
body in diabetic DBA/2J mice. Diabetes was induced with
multiple low-dose STZ injections, and to further promote
a renal phenotype, mice were fed a high-fat diet (HFD)
similar to previous studies (Wang et al. 2009). The meta-
bolic characteristics of the DBA/2J mice are depicted in
Table 1. At the end of the study, diabetic mice showed
threefold higher average fasting blood glucose levels,
which were not affected by anti-IL-1b treatment. How-
ever, the diabetes-associated elevation of serum FetA
levels (88  16%, P < 0.001) was significantly attenuated
by anti-IL-1b antibody 63  5% (P < 0.001; Fig. 5A).
As previous studies linked an increase in urinary TNF-
a levels to the progression of albuminuria (Kalantarinia
et al. 2003; Wu et al. 2013), we investigated whether
treatment with the anti-IL-1b antibody affects urinary
TNF-a levels in diabetic DBA/2J mice. Indeed, diabetic
mice showed increased urine TNF-a levels (69  19%,
P < 0.01) compared to nondiabetic controls. Intriguingly,
diabetic mice treated with the anti-IL-1b antibody
revealed 71  20% (P < 0.001) lower TNF-a levels in the
urine (Fig. 5B). To address whether the treatment has any
renoprotective effects, urinary albumin levels were deter-
mined as a marker for kidney filter integrity. Even though
diabetic DBA/2J mice had elevated albumin levels in the
urine (299  74%, P < 0.01; Fig. 5C) after a follow-up of
4 weeks, not unexpectedly the levels were only moderately
increased. Therefore, future long-term studies have to
address whether neutralizing IL-1b can prevent the pro-
gression of DN. However, these findings indicate that a
therapy targeting IL-1b can prevent the diabetes-asso-
ciated increase in urine TNF-a levels and serum FetA,
which are risk factors for the development of DN.
Discussion
In the present study, we demonstrate that FetA aggravates
palmitic acid-induced podocyte death. This effect is asso-
ciated with an inflammatory response and involves IL-1b
signaling.
Several lines of evidence suggest that the deleterious
effect of FetA may involve TLR4 signaling. Specifically,
using genetically engineered HEK-Blue hTLR4 cells as a
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represent mean  SD MCP-1 levels (in pg/mL) in the supernatant after 1 h of preincubation and treatment for 16 h (n = 3, *P < 0.05,
**P < 0.01, ***P < 0.001).
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reporter system FetA led to a dose-dependent (range of
50–150 lg/mL) TLR4 activation in the presence of
150 lmol/L palmitic acid. Using the same assay, it was
previously shown that FetA alone or combined with pal-
mitic acid activates TLR4, though palmitic acid alone had
no significant effect (Pal et al. 2012). A similar response
was observed with the prototypical TLR4 ligand LPS. In
contrast to FetA, the dose of LPS was increased logarith-
mically from 10 to 104 pg/mL. This suggests that the
mechanism of FetA on TLR4 may differ from LPS. To
minimize interference with any residual endotoxin con-
tamination, FetA as well as all FFA complexes were puri-
fied using polymyxin B columns. Of interest, the effect of
FetA on the HEK-Blue-hTLR4 reporter cell line was only
observed with murine but not with bovine FetA (data not
shown) suggesting a species-dependent and potentially a
glycosylation-dependent receptor activation (Pal et al.
2012). However, in podocytes both bovine and murine
FetA significantly stimulated MCP-1 release (Figs. 1A, C,
and 3), which was further increased by palmitic acid.
Consistent with the reporter assay data, the specific TLR4
inhibitor TAK-242 (Matsunaga et al. 2011) prevented the
MCP-1 release in podocytes (Figs. 1C and 3) and our
data suggest that the observed proinflammatory response
involves TLR4 signaling.
Interestingly, and in contrast to previous studies using
other cells including pancreatic b-cells (Lee et al. 2001;
Shi et al. 2006; Boni-Schnetzler et al. 2009), no stimula-
tion of MCP-1 or KC could be observed in podocytes
incubated with palmitic acid alone, although palmitic
acid together with FetA exacerbated the inflammatory
response. This may be explained by inherent differences
of specific cell types. Alternatively, most cell culture
studies are performed with 10% FBS, which contains
about 20 mg/mL FetA (Pal et al. 2012). Previously, it
has been suggested that FetA, FFAs, and TLR4 build a
ternary complex (Pal et al. 2012) though part of the evi-
dence for a direct interaction of FetA and TLR4 results
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from a yeast two-hybrid assay and needs further explana-
tion as glycosylation of FetA has been shown to be criti-
cal (Pal et al. 2012). Clearly, more experiments are
needed to clarify the exact interplay between FetA, FFAs,
and TLR4.
Of note, both FetA and LPS had no effect on podocyte
survival, but exacerbated palmitic acid-induced podocyte
death, and this could be partially prevented by the TLR4
inhibitor TAK-242 (Fig. 2A and B). The finding that LPS
exacerbated palmitic acid-induced podocyte death may at
least in part explain albuminuria in septic patients (Basu
et al. 2010) as bacterial endotoxins and FFAs are
increased in this setting (Nogueira et al. 2008). Of note,
endotoxin levels are also reported to be elevated in
patients with metabolic syndrome and may contribute to
the progression of DN (Lassenius et al. 2011).
Table 1. Metabolic characteristic of DBA/2J mice experiments
Control + Saline Control + Anti-IL-1b Ab STZ (HFD) + Saline STZ (HFD) + Anti-IL-1b Ab
Age (weeks) at the start of experiment
or induction of diabetes
9 9 9 9
Weight at induction of diabetes (g) 26.5  0.96 26.5  1.82 25.8  1.53 25.7  1.35
Weight at the end of experiment (g) 33.3  2.35 33.3  2.85 24.8  2.06 25.5  1.67
Fasting blood glucose (mmol) at 10 days
after STZ injection
5.5  0.88 5.6  0.27 11.2  2.55 12.0  2.48
Fasting glucose (mmol) at the end of experiment 5.8  1.72 5.4  0.86 17.4  2.06 18.0  2.04
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Unexpectedly, TAK-242 dramatically reduced palmitic
acid-induced podocyte death. Even though FetA, BSA,
and FFAs complexed to BSA were purified from endo-
toxin with polymyxin B, stimulation of TLR4 by a resid-
ual endotoxin contamination, though unlikely, cannot be
completely excluded. If so, the residual endotoxin concen-
tration would be in the lower range of healthy human
blood donors, reported to be between 1.00 and 0.01 EU/
mL (Nadhazi et al. 2002). Alternatively, the protective
effect of TAK-242 on palmitic acid-induced podocyte
death can be explained by a constitutively active TLR4 in
podocytes. Although TAK-242 binds specifically to an
intracellular domain of TLR4 (Matsunaga et al. 2011), we
cannot rule out additional protective off-target effects.
An interesting outcome of the current study was that
inhibition of IL-1 signaling by anakinra, a recombinant
human IL-1Ra, or a murinized anti-IL-1b antibody could
attenuate the inflammatory response elicited by FetA and
palmitic acid. In addition, anakinra and the anti-IL-1b
antibody attenuated podocyte death induced by palmitic
acid alone or in combination with FetA. This clearly indi-
cates that palmitic acid-induced podocyte death is partially
mediated by IL-1, even more specifically by IL-1b. Interest-
ingly, podocyte death could not be induced by IL-1b alone,
as it was previously reported for pancreatic beta-cells (Mae-
dler et al. 2004), however, IL-1b was able to exacerbate pal-
mitic acid-induced podocyte death. Together this indicates
that the proapoptotic effect of IL-1b in podocytes depends
on a second insult elicited by palmitic acid or by the com-
bination of palmitic acid and FetA. Of interest, the protec-
tive effects of anakinra and the anti-IL-1b antibody on
podocytes exposed to FetA and/or palmitic acid implies the
presence of IL-1b; however, IL-1b levels in the cell culture
media of treated podocytes were in the signal noise. This is
a well-known phenomenon as IL-1b is highly active and
levels are often under the detection limit of conventional
assays and the involvement of IL-1b can only be demon-
strated indirectly, by its neutralization (Marianne B€oni-
Schnetzler, pers. comm.).
In a pilot short-term study, we investigated the effect of
a murinized anti-IL-1b antibody in insulinopenic DBA/2J
mice (STZ model) fed a high-fat diet. Treatment with the
anti-IL-1b antibody suppressed the increase in urinary
TNF-a levels observed in diabetic mice. This may be rele-
vant as urinary TNF-a is a risk factor for albuminuria
(Kalantarinia et al. 2003), and TNF-a is reported to
induce podocyte death (Ryu et al. 2012; Tejada et al.
2008, and our unpublished data). Of importance, treat-
ment with the anti-IL 1b antibody prevented the increase
in serum FetA levels. In this context, a community-based
study in China is noteworthy as people in the highest FetA
tertile had a twofold increased risk for developing albu-
minuria over a follow-up period of 4 years (Lv et al.
2016). This could potentially indicate that the lower serum
FetA concentrations together with the reduced urinary
TNF-a levels observed in mice treated with the anti-IL-1b
antibody may predict long-term protection by the anti-IL-
1b antibody against DN. Of note, urinary FetA levels were
under the detection limit (data not shown), though in a
human study in patients with type 2 diabetes urinary FetA
was identified as a new risk factor for renal injury (Inoue
et al. 2013). In this short-term diabetes model, diabetic
mice did not develop kidney pathologies. Even though
urine albumin excretion is significantly increased in dia-
betic mice, this increase was very limited, and therefore,
further in vivo studies with a longer follow-up are needed
to investigate the effect of the anti-IL-1b antibody for the
prevention and treatment of DN. An apparent limitation
of the current study is that we do not know whether STZ
diabetes, HFD, or their combination lead to an increase in
serum FetA and urinary TNF-a which can be prevented by
anti-IL-1b treatment, and additional control groups with
STZ-diabetes and HFD alone need to be included in
future experiments. Furthermore, a recent study in mice
deficient in NLRP3 (nucleotide-binding domain and leu-
cine-rich repeat pyrin 3 domain) in nonmyeloid-derived
cells linked inflammasome formation, which activates cas-
pase-1, and thus maturation of IL-1b (Kumar and Anders
2014), to the pathogenesis of DN (Shahzad et al. 2015). In
addition, the same study reports that anakinra can protect
from or even reverse the course DN in several mouse
models (Shahzad et al. 2015).
In summary, our results suggest that FetA leads to an
inflammatory response in podocytes, which is further
enhanced by palmitic acid and exacerbates palmitic acid-
induced podocyte death. They underscore the role of
TLR4 signaling in the proinflammatory effect of FetA. In
addition, our data support a critical role for IL-1 signal-
ing in palmitic acid-induced podocyte death. In vivo
treatment with an anti-IL-1b antibody prevented an
increase in serum FetA concentrations and suppressed
urinary TNF-a levels in diabetic mice. These findings
offer the rationale for future studies addressing the long-
term effects of IL-1b signaling inhibition on the develop-
ment and course of DN.
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